To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
383 Current news of Merckrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Company will focus on process development and improvements for manufacturing Baylor’s Covid-19 vaccine candidates
Merck and Baylor College of Medicine, Houston, Texas, USA, announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials. “Vaccine manufacturing is extremely complicated, so we are ...
New, € 100 million facility will more than double existing production capacity
Merck announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, €100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the ...
Joint team reduced process development time to two months from a year
Merck and The Jenner Institute announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a ...
CRISPR-chrom technology improves access to genome for more efficient editing
Merck announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology. With this allowance, Merck is the only provider with a patent covering the fusion of chromatin modulating peptides to CRISPR proteins, helping to clear chromatin out of ...
Merck met all its financial targets and thus grew profitably in fiscal 2019. At the same time, Merck also made significant progress in executing its strategic agenda. “We delivered on our promise and achieved growth for all our key performance indicators, namely net sales, EBITDA pre and EPS pre. ...
Merck and AMCM cooperate
Merck and AMCM, Starnberg, Germany, announced a cooperation agreement on the 3D printing of tablets. AMCM offers customized additive manufacturing solutions. The cooperation targets GMP-conform (Good Manufacturing Practice) tablet formulation development and production for clinical trials in a ...
Merck signed an agreement to sell its allergy business Allergopharma to Dermapharm Holding SE. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions. Since 2007, Merck has made ...
Liquid biopsy kits aim to improve accuracy of cancer diagnosis
Merck announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types, making diagnoses more accurate. “Both small and large ...
Merck announced an investment of €250million in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies. Driven by the growth of the Healthcare business sector R&D pipeline, this investment ...
Merck announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA access to Merck’s foundational CRISPR intellectual property. Promega will use Merck’s CRISPR genome-editing technology to create research products ...